Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept
Strober B, Gottlieb A, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl M. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal Of The American Academy Of Dermatology 2017, 76: 655-661. PMID: 28087133, DOI: 10.1016/j.jaad.2016.11.043.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentsDouble-Blind MethodEtanerceptFemaleHumansImmunosuppressive AgentsInjections, SubcutaneousInterleukin-17MaleMiddle AgedPatient SatisfactionPsoriasisQuality of LifeRecurrenceSurveys and QuestionnairesTreatment OutcomeTumor Necrosis Factor-alphaConceptsDermatology Life Quality IndexWeek 24Secukinumab treatmentWeek 52Phase III randomized placebo-controlled clinical trialsRandomized placebo-controlled clinical trialPatient-reported health-related qualityPlacebo-controlled clinical trialGreater sustained improvementsGreater clinical responseHealth-related qualityLife Quality IndexProportion of subjectsQuality of lifeSevere psoriasisClinical responsePlacebo comparisonPsoriasis AreaMedian timePatients' qualityWeek 12Chronic conditionsOutcome benefitsSafe treatmentClinical trials